169 results
Page 4 of 9
8-K
EX-99.1
nrkp rwqca
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
ynf wfgvvhk
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
zs1s1k2
17 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-3.1
id0u lpdrukn0n
17 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-99.1
zefdb7k0 tk5g
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
spbp82u vy5
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-10.1
z3b u6emd5371
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.2
9xliutpubu ut
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.2
muwtuovp
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.3
scdnsu04hhq5hdr9nd
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.1
wfbny kb4h6onxoz0vq
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-99.1
3a3tydpxz4ohtiaibad
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
cwt5z
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
zfyl8z
5 May 20
Prospectus supplement for primary offering
5:05pm
DEFA14A
n5fbf0u cwioh
9 Apr 20
Additional proxy soliciting materials
4:11pm
8-K
EX-99.1
nsw4osoe
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
8-K
EX-1.1
h7mut 1umwq9
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm